Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This project is part of the Therapeutic Genomics Centre, a multidisciplinary programme of innovative approaches to treating rare genetic disorders and providing an enhanced training experience for DPhil applicants.

Academic Supervisors: Prof. Sarah Wordsworth, Assoc. Prof. Nicky Whiffin

Other Supervisors: Dr. Padraig Dixon

Host Dept: Nuffield Department of Population Health (NDPH), Oxford

A major hurdle for moving genome-targeted therapies such as antisense oligonucleotides (ASO) and CRISPR-editing into routine care is the health technology assessment (HTA) process and demonstrating cost-effectiveness to agencies such as NICE. Few health economic assessments have been carried out in this area, with methodological challenges in evaluating genome-targeted therapies noted. Challenges include deciding which health and non-health outcomes to assess and which measurement instruments to use, dealing with small sample sizes, whether to apply an inflationary factor to quality-adjusted life years (QALYs) or to use a higher cost-effectiveness threshold and considering other forms of economic evaluation, including cost-benefit analysis.

This DPhil project will perform much-needed early health economic analysis, including exploring hospital episode statistics data from Genomics England (GEL) patients to examine how healthcare costs could be avoided or reduced if genome-targeted therapies are used. We will test potential solutions to methodological challenges to prepare the evaluation pipeline for HTA agencies. Finally, stakeholder preferences for using genome-targeted therapies will be elicited to identify barriers influencing therapy uptake.

This DPhil project is important to the Therapeutic Genomics Centre to help ensure that any significant scientific and clinical breakthroughs are not left in an endless cycle of reimbursement rejections due to limitations in the current HTA process.

Studentship code: MRCTGCORE2024003

Please read these guidance notes for detail on how to apply

Click here to apply: IPP login screen (ox.ac.uk)

For more information on DPhil in Paediatrics: DPhil in Paediatrics | University of Oxford

For more information about our MRC-Oxford Doctoral Training Programme see: https://www.medsci.ox.ac.uk/study/graduateschool/mrcdtp